Gland Pharma Ltd

Gland Pharma Ltd is up for a fifth straight session today. The stock is quoting at Rs 1781.7, up 0.08% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.62% on the day, quoting at 25402.2. The Sensex is at 83287.99, up 0.64%. Gland Pharma Ltd has gained around 16.61% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has gained around 0.94% in last one month and is currently quoting at 21804.8, down 0.35% on the day. The volume in the stock stood at 1.35 lakh shares today, compared to the daily average of 1.72 lakh shares in last one month.The PE of the stock is 26.95 based on TTM earnings ending March 25.Powered by Capital Market - Live

Gland Pharma announced that following the Pre-approval inspection (PAI) for Sterile APIs at the Company's Facility at JNPC, Visakhapatnam between 19 February 2025, and 25 February 2025; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection. Powered by Capital Market - Live

As per the exchange filing dated 25 February 2025, the USFDA had conducted a pre-approval inspection (PAI) for sterile APIs at the company's facility located at JNPC, Visakhapatnam, between 19 February and 25 February 2025. The inspection concluded with three Form 483 observations, which the company clarified were procedural in nature. The firm stated that these are not repeated observations and are unrelated to data integrity. The company intends to submit the required corrective and preventive actions (CAPA) to the USFDA within the stipulated timeline. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered heparin technology in India. The company's consolidated net profit declined 3.06% to Rs 186.54 crore as net sales fell by 7.32% to Rs 1424.91 crore in Q4 FY25 as compared with Q4 FY24. Powered by Capital Market - Live

Gland Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 1793.5, up 1.28% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.43% on the day, quoting at 24840.25. The Sensex is at 81449.59, down 0.42%. Gland Pharma Ltd has risen around 20.86% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has risen around 0.24% in last one month and is currently quoting at 22039.45, down 1.59% on the day. The volume in the stock stood at 2.97 lakh shares today, compared to the daily average of 1.95 lakh shares in last one month.The PE of the stock is 26.75 based on TTM earnings ending March 25.Powered by Capital Market - Live

Gland Pharma Ltd is up for a fifth straight session today. The stock is quoting at Rs 1650.9, up 0.15% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.13% on the day, quoting at 25136.5. The Sensex is at 82493.19, up 0.06%. Gland Pharma Ltd has gained around 15.44% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has gained around 3.79% in last one month and is currently quoting at 21826.8, up 0.35% on the day. The volume in the stock stood at 52199 shares today, compared to the daily average of 1.68 lakh shares in last one month.The PE of the stock is 24.92 based on TTM earnings ending March 25.Powered by Capital Market - Live

The domestic equity indices continued to trade with decent gains in morning trade, maintaining upward momentum, as investor sentiment remained upbeat ahead of the upcoming RBI policy meeting. However, market participants will closely track domestic economic indicators, Brent crude oil prices and global trade development. The Nifty traded above the 24,550 mark. Realty shares declined, as investors booked profits following gains in the previous two trading sessions. At 10:25 IST, the barometer index, the S&P BSE Sensex, 169.01 points or 0.21% to 80,906.52. The Nifty 50 index added 47.75 points or 0.20% to 24,590.60. In the broader market, the S&P BSE Mid-Cap index rose 0.20% and the S&P BSE Small-Cap index added 0.23%. The market breadth was positive. On the BSE, 1,872 shares rose and 1,691 shares fell. A total of 229 shares were unchanged. The Reserve Bank of India commenced its monetary policy meeting today, 4 June 2025, which will conclude on 6 June 2025. The meeting is being chaired by Governor Sanjay Malhotra. With inflation showing signs of moderation, market participants are speculating on the possibility of a rate cut. New Listing: Shares of Scoda Tubes were currently trading at Rs 146.95 at 10:26 IST on the BSE, representing a premium of 4.96% compared with the issue price of Rs 140. The scrip was listed at 140, matching the initial public offer (IPO) price. The stock was currently up 4.96% over its listing price. So far, the stock has hit a high of 146.95 and a low of 136. On the BSE, over 4.38 lakh shares of the company were traded in the counter so far. Buzzing Index: The Nifty Realty index declined 0.67% to 976.35. The index jumped 3.53% in the past two trading sessions. Brigade Enterprises (down 2.09%), Anant Raj (down 1.97%), Phoenix Mills (down 1.86%), Oberoi Realty (down 1.56%), Godrej Properties (down 1.07%), DLF (down 0.65%), Sobha (down 0.46%) and Raymond (down 0.41%) declined. Stocks in Spotlight: Gland Pharma advanced 1.21% after the company said that it has received approval from the United States Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for Angiotensin II Acetate Injection. Servotech Renewable Power surged 12.12% after the company received a significant order for a 7.8 MW grid-connected solar rooftop project by the Rangiya Division of the Northeast Frontier Railway. The order, valued at Rs. 336 Million, also includes a comprehensive 5-year Annual Maintenance Contract (AMC)/Comprehensive Annual Maintenance Contract (CAMC) for various buildings within the Rangiya Division. R Systems International added 1.66% after the company announced strategic partnership with Mavvrik, a leader in AI cost governance, to help enterprises gain visibility and precise financial control over rapidly escalating AI, cloud, and hybrid infrastructure investments.Powered by Capital Market - Live

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD) GIAPREZA of La Jolla Pharma LLC. This product is indicated for increasing the blood pressure in adults with septic or other distributive shock. Gland Pharma is the exclusive first-to-file and is eligible for 180 days of generic drug exclusivity. According to IQVIA, the product had US sales of approximately $58 million for the twelve months ending March 2025. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered heparin technology in India. The company's consolidated net profit declined 3.06% to Rs 186.54 crore as net sales fell by 7.32% to Rs 1424.91 crore in Q4 FY25 as compared with Q4 FY24. The scrip rose 0.32% to currently trade at Rs 1598.95 on the BSE. Powered by Capital Market - Live

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Angiotensin II Acetate Injection 2.5 mg/mL. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), GIAPREZA ' of La Jolla Pharma LLC. This Product is indicated for increasing the blood pressure in adults with septic or other distributive shock. Gland Pharma is the exclusive First-to-File and is eligible for 180 days of generic drug exclusivity. According to IQVIA, the product had US sales of approximately USD 58 million for the twelve months ending March 2025.Powered by Capital Market - Live

Gland Pharma announced that the Annual General Meeting(AGM) of the company will be held on 28 August 2025.Powered by Capital Market - Live

Net profit of Gland Pharma declined 3.06% to Rs 186.54 crore in the quarter ended March 2025 as against Rs 192.42 crore during the previous quarter ended March 2024. Sales declined 7.32% to Rs 1424.91 crore in the quarter ended March 2025 as against Rs 1537.45 crore during the previous quarter ended March 2024. For the full year,net profit declined 9.57% to Rs 698.53 crore in the year ended March 2025 as against Rs 772.46 crore during the previous year ended March 2024. Sales declined 0.85% to Rs 5616.50 crore in the year ended March 2025 as against Rs 5664.72 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales1424.911537.45 -7 5616.505664.72 -1 OPM %24.3923.33 -22.5923.53 - PBDT384.09390.84 -2 1440.531477.11 -2 PBT288.33298.23 -3 1062.661132.54 -6 NP186.54192.42 -3 698.53772.46 -10 Powered by Capital Market - Live